Advertisement

Topics

Jecure Therapeutics Inc. Company Profile

13:00 EST 15th December 2018 | BioPortfolio

Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis. Jecure’s scientific founder is Dr. Ariel Feldstein, Division Chief of Gastroenterology at UCSD School of Medicine and a leading physician scientist in hepatology. With operations in the biotech hub of San Diego, California, Jecure combines emerging NASH biology from Dr. Feldstein’s lab, a proprietary liver disease platform and an elite discovery team of veteran pharma/biotech scientists. Jecure’s lead program has identified small molecule inhibitors of the NLRP3 inflammasome, a novel target and pro-inflammatory driver of NASH. Jecure is backed by top-tier life science investor Versant Ventures. For more information, please visit www.jecuretx.com.


News Articles [716 Associated News Articles listed on BioPortfolio]

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CE...

Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics

Roche is acquiring San Diego startup Jecure Therapeutics, with hopes of turning Jecure’s early research into a drug or drugs that treat the liver disease NASH. Through its South San Francisco, C...

Roche subsidiary Genentech to acquire Jecure Therapeutics

Swiss firm Roche Group’s affiliate Genentech has agreed to acquire US biotechnology company Jecure Therapeutics to strengthen its position in...Read More... The post Roche subsidiary Genentech to ac...

Genentech Takes Jecure Therapeutics

Genentech, part of Swiss drugs giant Roche, has agreed to buy Jecure Therapeutics, a US biotech focused on discovering novel treatments for non-alcoholic steatohepatitis (NASH) and liver  fibrosi...

Genentech Gains Rights to Portfolio of NLRP3 Inhibitors through Acquisition of Jecure Therapeutics

SAN DIEGO–(BUSINESS WIRE)–Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreeme...

Genentech Takes Aim at NASH, Acquires Jecure Therapeutics

Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.

Roche buys biotech Jecure

The group's subsidiary Genentech will acquire Jecure Therapeutics, which is a biotech company based in the U.S. with novel drug discovery programs targeting serious inflammatory diseases

Roche buys biotech company Jecure

The group's subsidiary Genentech will acquire Jecure Therapeutics, which is a biotech company based in the U.S. with novel drug discovery programs targeting serious inflammatory diseases

PubMed Articles [460 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1285 Associated Companies listed on BioPortfolio]

Jecure Therapeutics Inc.

Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis. Jecure’s scientific founder is Dr. Ariel Feldstein, Divisi...

Jecure Therapeutics

Jecure is focused on the discovery of novel therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure’s scientific founder is Dr. Arie...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Jecure Therapeutics Inc." on BioPortfolio

We have published hundreds of Jecure Therapeutics Inc. news stories on BioPortfolio along with dozens of Jecure Therapeutics Inc. Clinical Trials and PubMed Articles about Jecure Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Jecure Therapeutics Inc. Companies in our database. You can also find out about relevant Jecure Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...


Corporate Database Quicklinks



Searches Linking to this Company Record